Complement Pharma focuses on developing innovative therapies aimed at addressing unmet medical needs, particularly in the field of complement-mediated diseases. The company leverages advanced scientific research to create novel treatments that modulate the complement system, a crucial part of the immune response. Their pipeline includes a range of products designed to target specific pathways within this system, showcasing their commitment to precision medicine and tailored therapeutic approaches.

The company emphasizes a strong foundation in scientific expertise and collaboration, which is essential for driving their research and development efforts. By integrating cutting-edge technologies and methodologies, Complement Pharma aims to enhance the efficacy and safety of their therapeutic candidates. Their strategic focus on complement biology positions them to make significant contributions to the treatment landscape for various diseases, ultimately improving patient outcomes.

Netherlands

Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system.  With a focus on C6 we aim to fight neurodegeneration in indications like TBI, ALS and MS.  Our promising pre-clinical data, shows safety and efficacy of C6 inhibition to modify disease progression in the mentioned indications and beyond.  Our first antibody, with excellent characteristics is now getting ready for GMP production and clinical trials.  In June 2018 Alexion and Complement Pharma announced their collaboration to develop C6 complement inhibitor CP010 for neurodegenerative disorders.

Complement Pharma

Company Details